CLCM
RETA

Crawford Lake Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Crawford Lake Capital Management’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-14,780
Closed -$1.21M – 86
2018
Q3 		$1.21M Buy
+14,780
New +$1.04M 0.23% 53

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Crawford Lake Capital Management's RETA Position: Q4 2018 in Review

Crawford Lake Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2018, closing a stake of 14,780 shares — an estimated $1.21M sold.

Crawford Lake Capital Management first reported a position in RETA in Q3 2018 and held it in 1 quarter. The position peaked at $1.21M in Q3 2018. 131 funds tracked by Wall St. Rank hold RETA as of Q4 2018.

  • Crawford Lake Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2018 after selling out during the quarter.
  • Crawford Lake Capital Management sold 14,780 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2018, an estimated $1.21M.
  • Crawford Lake Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2018 and held it in 1 quarter.
  • Crawford Lake Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.21M in Q3 2018.
  • 131 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2018.

Based on Crawford Lake Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.